Komori
Qualtec (9165) · RiskRestated

Ongoing Order Acquisition

First written in FY2023. 4 of 6 entries say "Restated". Latest entry: FY2025.

6entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2024-Q2 – FY20252023: 220232024: 320242025: 12025
Same theme, other companies
Expanding Orders and Sales Channels by Strengthening Sales CapabilitiesA theme 177 companies write about · 1 as a headwind · 184 as a tailwind

51 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 177 companies compared. The sentences above are computed from all 177.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「We believe that continuously securing orders and having customers continue to use our services are important to the growth of our business.」

    The company continues to regard sustained order acquisition as an important prerequisite for growth and continues to expand services, improve quality and conduct sales activities.
  2. FY2024RestatedAnnual report

    「We believe that continuously securing orders and having customers continue to use our services are important to the growth of our business.」

    The company continues to regard sustained order acquisition as essential to growth and addresses the risk through service expansion, quality improvements and sales activities.
  3. FY2024-Q3RestatedAnnual report

    「In the bio business within the Other Business, demand for pet purchases has continued not to recover, and as a result orders for genetic testing remain weak.」

    Weak demand for pet purchases continues to weigh on genetic-testing orders.
  4. FY2024-Q2RestatedAnnual report

    「Demand for pet purchases has continued not to recover, and as a result orders for genetic testing remain weak.」

    Weak demand for pet purchases continues to weigh on orders for genetic testing.
  5. FY2024-Q1MaterialisedAnnual report

    「Orders for board evaluation in the surface treatment technology business included in the Other Business remained strong. However, orders for genetic testing in the bio business declined because demand for genetic testing fell as demand for pet purchases weakened and competitors entered the market.」

    The company reports that demand declines and competitor entry have resulted in an actual decline in genetic-testing orders.
  6. FY2023First statedAnnual report

    「If we are unable to provide services that meet demand or sales activities do not produce sufficient results, new orders and orders from existing customers may decline, which may affect our business results and financial position.」

    The company’s countermeasures are to expand and improve its services and conduct sales activities targeting potential customers.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Qualtec yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Ongoing Order Acquisition | Qualtec Co.,Ltd. (9165) | Komori